Core Insights - Chemomab Therapeutics Ltd. is a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need [3] - The company will present at the virtual Oppenheimer 35 Annual Healthcare Life Sciences Conference on February 11, 2025, with a live webcast available for 90 days [1][2] Company Overview - Chemomab is developing CM-101, a first-in-class dual activity monoclonal antibody that neutralizes the soluble protein CCL24, which plays a role in fibrosis and inflammation [3] - CM-101 has shown a favorable safety profile and potential to treat multiple severe fibro-inflammatory diseases, with positive results reported from four clinical trials [3] - The company anticipates achieving a clear FDA registrational pathway for the planned Phase 3 pivotal trial of CM-101 in primary sclerosing cholangitis (PSC) and reporting data from the SPRING trial open label extension in early 2025 [3] - CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC treatment [3] - The program for systemic sclerosis treatment is Phase 2-ready with an open U.S. IND [3]
Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference